Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: pioglitazone/placebo Clear all

Conditions: Polycystic Ovary Syndrome
Interventions: pioglitazone, metformin, placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg; Drug
Lead sponsor: Metabolic Solutions Development Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Los Angeles, California • Miami Gardens, Florida • West Palm Beach, Florida + 5 more

Conditions: Cocaine Use Disorder, Alcohol Use Disorder
Interventions: Pioglitazone, Placebo, Therapy, Contingency Management; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nonalcoholic Steatohapatitis
Interventions: Roflumilast, Pioglitazone, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Coronado, California • Annapolis, Maryland • Baltimore, Maryland

Conditions: ESRD
Interventions: anakinra, actos, placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity, Metabolic Syndrome
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Baton Rouge, Louisiana

Conditions: Cocaine Use Disorder
Interventions: Cognitive Behavioral Therapy (CBT), Pioglitazone, Placebo; Behavioral · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bipolar Disorder, Insulin Resistance
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Impaired Glucose Tolerance, Type 2 Diabetes
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 5 more

Conditions: Obesity
Interventions: Immediate weight loss, Pioglitazone, Deferred weight loss, Placebo; Behavioral · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 29
States / cities: Escondido, California • Greenbrae, California • Los Angeles, California + 25 more

Conditions: Uric Acid Kidney Stone Disease
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Insulin Resistance, Type 2 Diabetes Mellitus
Interventions: pioglitazone, nateglinide, placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 55 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: Vildagliptin, pioglitazone, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Type 2 Diabetes
Interventions: Pioglitazone and Azilsartan, Pioglitazone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 59
States / cities: Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more

Conditions: Type 2 Diabetes Mellitus
Interventions: MBX-102, Placebo, Actos, Metformin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more

Conditions: Chronic Kidney Disease
Interventions: Pioglitazone, Placebo, Nitroglycerin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Mild Cognitive Impairment
Interventions: Pioglitazone, Placebo, Endurance Exercise Training; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Diabetes
Interventions: Pioglitazone then Placebo, Placebo then Pioglitazone; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 40 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Fatty Liver
Interventions: fenofibrate, pioglitazone, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity, Type 2 Diabetes
Interventions: pioglitazone, placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Oral Leukoplakia
Interventions: Pioglitazone hydrochloride, placebo, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 11
States / cities: Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 51
States / cities: Peoria, Arizona • Artesia, California • Concord, California + 48 more

Search by objective public record fields.

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

PPARγ Agonist Treatment for Cocaine Dependence

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women

Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention

Pioglitazone for the Treatment of Bipolar Depression

Actos Now for Prevention of Diabetes (ACT NOW)

Insulin Regulation of Lipolysis and Lipolysis Proteins

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Pathophysiology of Uric Acid Nephrolithiasis

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)

Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes

Insulin Resistance in Non-alcoholic Fatty Liver Disease

Pioglitazone on Pancreatic Steatosis and Bone Health

Pioglitazone for Oral Premalignant Lesions

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)